An elevated low-density lipoprotein cholesterol (LDL-C) level is a risk factor for cardiovascular disease, including ischemic stroke.
1 For patients with a history of ischemic stroke, an elevated LDL-C level is associated with an increased risk of subsequent major cardiovascular events.
2 More intensive compared with less intensive LDL-C–lowering statin-based therapies are associated with reduced major cardiovascular events in patients with established atherosclerotic cardiovascular disease.
3 However, the results of LDL lowering with statins in secondary stroke prevention trials are inconsistent. An initial meta-analysis of randomized clinical trials showed that intensive LDL-C reduction with statins was associated with a significantly reduced risk of recurrent stroke.
4 A subsequent meta-analysis of randomized clinical trials showed that statins were associated with a reduction in the risk of ischemic strokes and cardiovascular events, but the reduction of recurrent stroke did not reach statistical significance.
5 In addition to their LDL-C–lowering effects, statins may exhibit cardiovascular protection via their pleiotropic effects.
6,7 The antithrombotic effect of statins may provide additional reduction in ischemic events but may increase the risk of intracranial hemorrhage in patients with ischemic stroke.
7,8